Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Core Viewpoint - Traws Pharma is hosting a virtual investor event to discuss its investigational oral small molecule product candidates targeting respiratory viral diseases, specifically focusing on Tivoxavir marboxil for bird flu and Ratutrelvir for COVID-19 [1][2]. Group 1: Company Overview - Traws Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for critical threats to human health from respiratory viral diseases [9]. - The company is advancing investigational antiviral agents that exhibit potent activity against difficult-to-treat or resistant virus strains [9]. - Traws Pharma aims to utilize accelerated clinical trial strategies with a commitment to vulnerable patient populations [9]. Group 2: Product Candidates - Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed for single-dose treatment of bird flu and seasonal influenza, showing potent in vitro activity against various influenza strains, including H5N1 [3][10]. - Seasonal influenza represents a multi-billion dollar antiviral market opportunity, driven by global health organizations and government tenders, with potential upside from pandemic flu outbreaks [3]. - Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor for COVID-19, designed to be used without ritonavir, demonstrating in vitro activity against multiple COVID-19 strains [4][10]. - Phase 1 studies indicate that Ratutrelvir maintains target blood plasma levels approximately 13 times above the EC50, potentially reducing the risk of clinical rebound and long COVID [4][10]. Group 3: Market Opportunities - The COVID-19 treatment market represents a potential multi-billion dollar opportunity, highlighting the ongoing need for improved therapies [4][10]. - The significant public health risk posed by H5N1 bird flu underscores the importance of developing effective treatments, as indicated by Traws' preclinical proof-of-concept and Phase 1 studies [7].